- Arvinas (New Haven, CT)
- …therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC ( R ) Discovery Engine platform to engineer proteolysis targeting chimeras, or ... PROTAC ( R ) targeted protein degraders, that are designed to harness...Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of… more
- Arvinas (New Haven, CT)
- …therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC ( R ) Discovery Engine platform to engineer proteolysis targeting chimeras, or ... PROTAC ( R ) targeted protein degraders, that are designed to harness...Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of… more
- Mitsubishi Chemical Group (Jersey City, NJ)
- …pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines ... (SCI), and in high unmet areas in Immunology and Oncology . MTPA is rapidly expanding its operations across all...the United States, MTPA launched rare disease treatments including RADICAVA( R ) (edaravone) injectables in 2017 and RADICAVA( R )… more
- University of Virginia (Charlottesville, VA)
- …disorders of gut-brain interaction, aerodigestive disorders, intestinal rehabilitation, nutrition, and global health, 8 faculty provide a full array of pediatric ... interventional gastrointestinal procedures. The Division's research portfolio is focused on global health and includes NIH funding. Quality improvement efforts span… more